Media releases Keyword Search Clear 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 Published on: 29 June 2020 FDA approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer more Published on: 29 June 2020 Roche announces new data at the ISTH 2020 Congress, demonstrating ongoing commitment to advancing care for people with haemophilia A more Published on: 29 June 2020 Roche’s ENSPRYNG®️ (satralizumab) approved in Japan for adults and children with neuromyelitis optica spectrum disorder more Published on: 26 June 2020 Roche improves speed and accuracy of non-small cell lung cancer diagnosis with launch of automated digital pathology algorithm more Published on: 19 June 2020 Roche’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints more Published on: 18 June 2020 Roche’s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer more Published on: 13 June 2020 Positive phase III results for Venclexta/Venclyxto combination in acute myeloid leukaemia presented at EHA 2020 more Published on: 12 June 2020 Roche announces 2-year risdiplam data from SUNFISH and new data from JEWELFISH in infants, children and adults with spinal muscular atrophy (SMA) more Published on: 4 June 2020 Roche’s Elecsys IL-6 test receives FDA Emergency Use Authorization to help in identifying patients at high risk of severe inflammatory response more Published on: 2 June 2020 FDA approves Roche’s Tecentriq in combination with Avastin for people with the most common form of liver cancer more Published on: 29 May 2020 CHMP recommends EU approval of Roche’s Rozlytrek for people with NTRK fusion-positive solid tumours and for people with ROS1-positive, advanced non-small cell lung cancer more Published on: 29 May 2020 Updated data demonstrate Roche’s Alecensa increases overall survival rate for people with ALK-positive non-small cell lung cancer more Published on: 28 May 2020 Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time approved in Europe more Published on: 28 May 2020 Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia more Published on: 27 May 2020 Roche’s Port Delivery System with ranibizumab shows positive phase III results in neovascular age-related macular degeneration more Published on: 22 May 2020 Roche acquires Stratos Genomics to further develop DNA based sequencing for diagnostic use more Published on: 22 May 2020 New longer-term data reinforce safety of Roche’s satralizumab in adults and adolescents with neuromyelitis optica spectrum disorder more Published on: 19 May 2020 FDA approves Roche’s Tecentriq as a first-line monotherapy for certain people with metastatic non-small cell lung cancer more Published on: 15 May 2020 Roche launches new blood gas digital solution designed to improve patient care more Published on: 14 May 2020 Roche to present first clinical data on novel anti-TIGIT cancer immunotherapy tiragolumab at ASCO more Published on: 11 May 2020 A formative figure in the company's history: Roche Honorary Chairman Fritz Gerber dies at the age of 91 more Published on: 11 May 2020 Changes to the Roche Enlarged Corporate Executive Committee more Published on: 7 May 2020 New data at the ASCO20 Virtual Scientific Program reflects Roche’s commitment to accelerating progress in cancer care more Published on: 3 May 2020 Roche’s COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark more Published on: 28 April 2020 New 6-year data for Roche’s OCREVUS (ocrelizumab) show earlier treatment initiation nearly halves risk of needing walking aid in relapsing multiple sclerosis more Published on: 28 April 2020 Roche’s risdiplam shows significant improvement in survival and motor milestones in infants with Type 1 spinal muscular atrophy (SMA) more Published on: 22 April 2020 First quarter with 2% growth in Swiss francs, 7% at constant exchange rates more Published on: 21 April 2020 Roche receives FDA approval for cobas HPV test for use on the cobas 6800/8800 Systems to identify women at risk for cervical cancer more Published on: 20 April 2020 US FDA and EMA accept applications for Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time more Published on: 17 April 2020 Roche develops new serology test to detect COVID-19 antibodies more Published on: 7 April 2020 Roche provides regulatory update on risdiplam for the treatment of spinal muscular atrophy (SMA) more Published on: 24 March 2020 Roche response to COVID-19 pandemic more Published on: 23 March 2020 Roche announces Venclexta/Venclyxto combination improved overall survival in people with previously untreated acute myeloid leukaemia more Published on: 19 March 2020 Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia more Published on: 17 March 2020 Roche Annual General Meeting 2020 more Published on: 16 March 2020 Roche Annual General Meeting 2020: Voting will take place by independent proxy. Participation on site is neither possible nor permitted by Federal Council ordinance more Published on: 14 March 2020 Roche Annual General Meeting 2020 to take place under special conditions set by the authorities - electronic voting strongly recommended more Published on: 13 March 2020 Roche’s cobas SARS-CoV-2 Test to detect novel coronavirus receives FDA Emergency Use Authorization and is available in markets accepting the CE mark more Published on: 12 March 2020 European Commission approves Venclyxto plus Gazyvaro for adults with previously untreated chronic lymphocytic leukaemia more Published on: 11 March 2020 Roche receives FDA approval for CINtec PLUS Cytology test to aid clinicians in improving cervical cancer prevention more Published on: 4 March 2020 FDA grants Breakthrough Device Designation for Roche's Elecsys GALAD score to support earlier diagnosis of hepatocellular carcinoma more Published on: 25 February 2020 FDA accepts Roche’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer more Published on: 19 February 2020 FDA grants priority review to Roche’s Tecentriq monotherapy as first-line treatment of certain people with advanced non-small cell lung cancer more Published on: 14 February 2020 China National Medical Products Administration grants approval of Roche’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer more Published on: 10 February 2020 Roche provides topline results from investigator-led Phase II/III trial with gantenerumab in rare inherited form of Alzheimer’s disease more Published on: 6 February 2020 Roche’s risdiplam showed significant improvement in motor function in people aged 2-25 with type 2 or 3 spinal muscular atrophy more Published on: 30 January 2020 Roche reports very strong results in 2019 more Published on: 27 January 2020 Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer more Published on: 24 January 2020 Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer more Published on: 23 January 2020 Roche’s Risdiplam meets primary endpoint in pivotal FIREFISH trial in infants with type 1 spinal muscular atrophy more Published on: 21 January 2020 European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma more Published on: 13 January 2020 Roche and Illumina partner to broaden patient access to genomic testing more
Published on: 29 June 2020 FDA approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer more
Published on: 29 June 2020 Roche announces new data at the ISTH 2020 Congress, demonstrating ongoing commitment to advancing care for people with haemophilia A more
Published on: 29 June 2020 Roche’s ENSPRYNG®️ (satralizumab) approved in Japan for adults and children with neuromyelitis optica spectrum disorder more
Published on: 26 June 2020 Roche improves speed and accuracy of non-small cell lung cancer diagnosis with launch of automated digital pathology algorithm more
Published on: 19 June 2020 Roche’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints more
Published on: 18 June 2020 Roche’s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer more
Published on: 13 June 2020 Positive phase III results for Venclexta/Venclyxto combination in acute myeloid leukaemia presented at EHA 2020 more
Published on: 12 June 2020 Roche announces 2-year risdiplam data from SUNFISH and new data from JEWELFISH in infants, children and adults with spinal muscular atrophy (SMA) more
Published on: 4 June 2020 Roche’s Elecsys IL-6 test receives FDA Emergency Use Authorization to help in identifying patients at high risk of severe inflammatory response more
Published on: 2 June 2020 FDA approves Roche’s Tecentriq in combination with Avastin for people with the most common form of liver cancer more
Published on: 29 May 2020 CHMP recommends EU approval of Roche’s Rozlytrek for people with NTRK fusion-positive solid tumours and for people with ROS1-positive, advanced non-small cell lung cancer more
Published on: 29 May 2020 Updated data demonstrate Roche’s Alecensa increases overall survival rate for people with ALK-positive non-small cell lung cancer more
Published on: 28 May 2020 Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time approved in Europe more
Published on: 28 May 2020 Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia more
Published on: 27 May 2020 Roche’s Port Delivery System with ranibizumab shows positive phase III results in neovascular age-related macular degeneration more
Published on: 22 May 2020 Roche acquires Stratos Genomics to further develop DNA based sequencing for diagnostic use more
Published on: 22 May 2020 New longer-term data reinforce safety of Roche’s satralizumab in adults and adolescents with neuromyelitis optica spectrum disorder more
Published on: 19 May 2020 FDA approves Roche’s Tecentriq as a first-line monotherapy for certain people with metastatic non-small cell lung cancer more
Published on: 15 May 2020 Roche launches new blood gas digital solution designed to improve patient care more
Published on: 14 May 2020 Roche to present first clinical data on novel anti-TIGIT cancer immunotherapy tiragolumab at ASCO more
Published on: 11 May 2020 A formative figure in the company's history: Roche Honorary Chairman Fritz Gerber dies at the age of 91 more
Published on: 7 May 2020 New data at the ASCO20 Virtual Scientific Program reflects Roche’s commitment to accelerating progress in cancer care more
Published on: 3 May 2020 Roche’s COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark more
Published on: 28 April 2020 New 6-year data for Roche’s OCREVUS (ocrelizumab) show earlier treatment initiation nearly halves risk of needing walking aid in relapsing multiple sclerosis more
Published on: 28 April 2020 Roche’s risdiplam shows significant improvement in survival and motor milestones in infants with Type 1 spinal muscular atrophy (SMA) more
Published on: 22 April 2020 First quarter with 2% growth in Swiss francs, 7% at constant exchange rates more
Published on: 21 April 2020 Roche receives FDA approval for cobas HPV test for use on the cobas 6800/8800 Systems to identify women at risk for cervical cancer more
Published on: 20 April 2020 US FDA and EMA accept applications for Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time more
Published on: 7 April 2020 Roche provides regulatory update on risdiplam for the treatment of spinal muscular atrophy (SMA) more
Published on: 23 March 2020 Roche announces Venclexta/Venclyxto combination improved overall survival in people with previously untreated acute myeloid leukaemia more
Published on: 19 March 2020 Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia more
Published on: 16 March 2020 Roche Annual General Meeting 2020: Voting will take place by independent proxy. Participation on site is neither possible nor permitted by Federal Council ordinance more
Published on: 14 March 2020 Roche Annual General Meeting 2020 to take place under special conditions set by the authorities - electronic voting strongly recommended more
Published on: 13 March 2020 Roche’s cobas SARS-CoV-2 Test to detect novel coronavirus receives FDA Emergency Use Authorization and is available in markets accepting the CE mark more
Published on: 12 March 2020 European Commission approves Venclyxto plus Gazyvaro for adults with previously untreated chronic lymphocytic leukaemia more
Published on: 11 March 2020 Roche receives FDA approval for CINtec PLUS Cytology test to aid clinicians in improving cervical cancer prevention more
Published on: 4 March 2020 FDA grants Breakthrough Device Designation for Roche's Elecsys GALAD score to support earlier diagnosis of hepatocellular carcinoma more
Published on: 25 February 2020 FDA accepts Roche’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer more
Published on: 19 February 2020 FDA grants priority review to Roche’s Tecentriq monotherapy as first-line treatment of certain people with advanced non-small cell lung cancer more
Published on: 14 February 2020 China National Medical Products Administration grants approval of Roche’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer more
Published on: 10 February 2020 Roche provides topline results from investigator-led Phase II/III trial with gantenerumab in rare inherited form of Alzheimer’s disease more
Published on: 6 February 2020 Roche’s risdiplam showed significant improvement in motor function in people aged 2-25 with type 2 or 3 spinal muscular atrophy more
Published on: 27 January 2020 Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer more
Published on: 24 January 2020 Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer more
Published on: 23 January 2020 Roche’s Risdiplam meets primary endpoint in pivotal FIREFISH trial in infants with type 1 spinal muscular atrophy more
Published on: 21 January 2020 European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma more
Published on: 13 January 2020 Roche and Illumina partner to broaden patient access to genomic testing more